{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(1)"],"submitter":["Kellner C"],"pubmed_abstract":["Antibody-dependent cell-mediated cytotoxicity (ADCC) mediated through the IgG Fc receptor FcγRIIIa represents a major effector function of many therapeutic antibodies. In an attempt to further enhance natural killer (NK) cell-mediated ADCC, we combined therapeutic antibodies against CD20 and CD38 with recombinant immunoligands against the stimulatory NK cell receptors NKG2D or NKp30. These immunoligands, respectively designated as ULBP2:7D8 and B7-H6:7D8, contained the CD20 scFv 7D8 as a targeting moiety and a cognate ligand for either NKG2D or NKp30 (i.e. ULBP2 and B7-H6, respectively). Both the immunoligands synergistically augmented ADCC in combination with the CD20 antibody rituximab and the CD38 antibody daratumumab. Combinations with ULBP2:7D8 resulted in higher cytotoxicity compared"],"journal":["Oncoimmunology"],"pagination":["e1058459"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4760288"],"repository":["biostudies-literature"],"pubmed_title":["Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30."],"pmcid":["PMC4760288"],"pubmed_authors":["Klausz K","Derer S","Parren PW","Kellner C","Peipp M","Humpe A","Kneba M","Gunther A","Gramatzki M","Repp R","Bruggemann M","Valerius T","van de Winkel JG","Ritgen M"],"additional_accession":[]},"is_claimable":false,"name":"Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.","description":"Antibody-dependent cell-mediated cytotoxicity (ADCC) mediated through the IgG Fc receptor FcγRIIIa represents a major effector function of many therapeutic antibodies. In an attempt to further enhance natural killer (NK) cell-mediated ADCC, we combined therapeutic antibodies against CD20 and CD38 with recombinant immunoligands against the stimulatory NK cell receptors NKG2D or NKp30. These immunoligands, respectively designated as ULBP2:7D8 and B7-H6:7D8, contained the CD20 scFv 7D8 as a targeting moiety and a cognate ligand for either NKG2D or NKp30 (i.e. ULBP2 and B7-H6, respectively). Both the immunoligands synergistically augmented ADCC in combination with the CD20 antibody rituximab and the CD38 antibody daratumumab. Combinations with ULBP2:7D8 resulted in higher cytotoxicity compared","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016","modification":"2026-05-05T11:41:27.917Z","creation":"2019-03-27T02:09:28Z"},"accession":"S-EPMC4760288","cross_references":{"pubmed":["26942070"],"doi":["10.1080/2162402x.2015.1058459","10.1080/2162402X.2015.1058459"]}}